Researchers in both Germany and Norway conducted studies that indicate linkages between the AstraZeneca/Oxford COVID-19 vaccine known as ChAdOx1 nCoV-19 and a rare response involving dangerous blood clotting linked to immune thrombotic thrombocytopenia, and the Germans from the Institute of Immunology and Transfusion Medicine even suggest naming the condition “vaccine-induced immune thrombotic thrombocytopenia (VITT).”
The researchers concluded that the ChAdOx1 nCoV-19 vaccine can actually result in a rare response: “the development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia.”
Researchers at the Institute of Immunology and Transfusion Medicine recently had a study published in New England Journal of Medicine (NEJM) evidencing linkages between the AstraZeneca/Oxford COVID-19 vaccine and a rare blood clotting disorder. Funded by the German Research Foundation, the study investigators identified 11 patients who were diagnosed with blood clots or low platelet levels from 5 to 16 days post the vaccine jab. Considered unusual thrombotic events as well as thrombocy...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).